

Resource Summary Report

Generated by [RRID](#) on Jul 31, 2026

FITC anti-mouse CD3

RRID:AB_312661

Type: Antibody

Proper Citation

BioLegend Cat# 100204, RRID:AB_312661

Antibody Information

URL: http://antibodyregistry.org/AB_312661

Proper Citation: BioLegend Cat# 100204, RRID:AB_312661

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_312661

Vendor: BioLegend

Catalog Number: 100204

Alternative Catalog Numbers: 100203

Record Creation Time: 20250820T030148+0000

Record Last Update: 20250820T150945+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-mouse CD3.

No alerts have been found for FITC anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 120 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Song X, et al. (2026) MHC-II-restricted neoantigen vaccine reverses immune microenvironment and overcomes resistance to immune-checkpoint inhibitors in cold tumors. *Med (New York, N.Y.)*, 7(1), 100936.

Li X, et al. (2026) The TCR-SUB1-DOCK2 axis promotes autoimmunity by driving pathogenic CD4+ T cell tissue infiltration. *Immunity*, 59(1), 98.

Chen Z, et al. (2026) Fibroblast-derived alarmin promotes oral wound healing by activating regulatory T cells that relay pro-angiogenic and anti-inflammatory responses. *Cell reports*, 45(1), 116829.

Thomas OG, et al. (2026) Anoctamin-2-specific T cells link Epstein-Barr virus to multiple sclerosis. *Cell*.

Dijkstra M, et al. (2025) Albumin-targeted oxaliplatin(iv) prodrugs bearing STING agonists. *Inorganic chemistry frontiers*, 12(13), 4284.

Cramer GM, et al. (2025) PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma. *Cancer research communications*, 5(5), 841.

Han S, et al. (2025) USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment. *Cancer immunology research*, 13(8), 1226.

Gawish R, et al. (2025) Filamin A editing in myeloid cells reduces intestinal inflammation and protects from colitis. *The Journal of experimental medicine*, 222(9).

Deng T, et al. (2025) CINTER-seq: Chemical profiling reveals interaction-dependent cell landscapes and gene signatures in vivo. *Immunity*, 58(9), 2336.

Pan Y, et al. (2025) Nuclear exosome targeting complex safeguards hematopoietic stem cell self-renewal and genomic integrity through resolving R loops. *Cell reports*, 44(12), 116650.

Wu J, et al. (2025) Vitamin B6 preserves the stemness-like phenotypes and antitumor ability of CD8⁺ T cells. *Developmental cell*.

Korah M, et al. (2025) Disruption of fibroblast MYD88 signaling promotes antitumor immunity in pancreatic ductal adenocarcinoma. *Cell reports*, 44(10), 116347.

Zhang Z, et al. (2025) Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. *Cell reports. Medicine*, 6(7), 102209.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. *Cancer cell*, 43(3), 503.

Chen Y, et al. (2025) Neoadjuvant chemotherapy by liposomal doxorubicin boosts immune protection of tumor membrane antigens-based nanovaccine. *Cell reports. Medicine*, 6(1), 101877.

Chen H, et al. (2025) Postprandial parasympathetic signals promote lung type 2 immunity. *Neuron*, 113(5), 670.

Singh ON, et al. (2025) Comparison of immunogenicity and protection efficacy of self-amplifying and circular mRNA vaccines against SARS-CoV-2. *iScience*, 28(10), 113498.

Peng Q, et al. (2025) RSK1 reprograms the ubiquitin pathway to promote immune suppression. *Cell reports*, 44(10), 116323.

Zhanzak Z, et al. (2025) Identification of indirect CD4⁺ T_H17 cell epitopes associated with transplant rejection provides a target for donor-specific tolerance induction. *Immunity*, 58(2), 448.

Gan L, et al. (2025) Acyloxyacyl Hydrolase Prevents Colitis and Colitis-Associated Colorectal Cancer by Inactivating Stimulatory LPS in the Intestine. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(8), e70566.